Aptamer Group publishes new Corporate Presentation and Investor Factsheet

Aptamer Group

Aptamer Group plc (LON:APTA), the leading developer of next generation synthetic binders delivering innovation to the life science industry, has announced that it has published a new corporate presentation and investor factsheet.

The corporate presentation outlines Aptamer’s strategy, operational progress and financial performance, offering a comprehensive overview of the Group’s growth potential. Complementing this, the investor factsheet provides a succinct two-page summary, focused on highlighting key operational and financial metrics to support investors in their evaluation of the Group.

No new material information has been disclosed in either of these publications.

We’ll keep you in the loop!

Join 1,000's of investors who read our articles first

We don’t spam! Read our privacy policy for more info.

Share on:
Find more news, interviews, share price & company profile here for:
    Aptamer Group plc reports impressive interim results for H1 2025, highlighting revenue growth and strategic advancements in life sciences innovation.
    Aptamer Group plc to announce interim results for six months ending December 2024, highlighting advancements in Optimer® binders for life sciences.
    Aptamer Group plc reports progress on key projects in its H1 2025 trading update, highlighting partnerships with Unilever and Alzheimer's biomarker validation.
    Aptamer Group plc (LON: APTA) secures a £155,000 contract to develop Optimer® binders for a rare disease biopharma, boosting clinical trial capabilities.
    Aptamer Group plc enhances its Scientific Advisory Board with three leading experts to drive innovation and commercialization in targeted therapy solutions.
    Aptamer Group plc (LON: APTA) updates on strategic programs with Unilever, Neuro-Bio, AstraZeneca, enhancing their Optimer® technology potential.

      Search

      Search